

CONSOLIDATED FINANCIAL STATEMENTS AND
SUPPLEMENTARY INFORMATION

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates
Year Ended March 31, 2020
With Report of Independent Auditors

Ernst & Young LLP



The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidated Financial Statements and Supplementary Information

Year Ended March 31, 2020

Contents

Report of Independent Auditors.....	1
Consolidated Financial Statements	
Consolidated Statement of Financial Position	3
Consolidated Statement of Activities.....	4
Consolidated Statement of Cash Flows	5
Consolidated Statement of Functional Expenses.....	6
Notes to Consolidated Financial Statements.....	7
Supplementary Information	
Consolidating Statement of Financial Position by Affiliate	24
Consolidating Schedule of Revenue and Functional Expenses by Affiliate.....	35



Ernst & Young LLP
One Victory Park
Suite 2000
2323 Victory Avenue
Dallas, TX 75219

Tel: +1 214 969 8000
Fax: +1 214 969 8587
ey.com

Report of Independent Auditors

The Board of Directors
The Susan G. Komen Breast Cancer Foundation, Inc.

We have audited the accompanying consolidated financial statements of The Susan G. Komen Breast Cancer Foundation, Inc. dba Susan G. Komen and Affiliates, which comprise the consolidated statement of financial position as of March 31, 2020, and the related consolidated statements of activities, cash flows, and functional expenses for the year then ended, and the related notes to the consolidated financial statements.

Management’s Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in conformity with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

Auditor’s Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying consolidating statement of financial position by Affiliate and the consolidating schedule of revenue and functional expenses by Affiliate are presented for purposes of additional analysis and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of The Susan G. Komen Breast Cancer Foundation, Inc. dba Susan G. Komen and Affiliates at March 31, 2020, and the changes in its net assets and its cash flows for the year then ended in conformity with U.S. generally accepted accounting principles.

Ernst + Young LLP

September 14, 2020

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidated Statement of Financial Position

March 31, 2020

Assets

Cash, cash equivalents, and restricted cash <i>(Note 1)</i>	\$ 62,456,354
Investments <i>(Note 2)</i>	115,861,335
Receivables, net <i>(Note 3)</i>	25,625,563
Prepaid expenses and other assets	2,632,854
Property, equipment, and intangible assets, net <i>(Note 1)</i>	993,409
Total assets	<u>\$ 207,569,515</u>

Liabilities and net assets

Accounts payable, accrued expenses, and other payables	\$ 8,037,032
Deferred revenue and rent	937,268
Grants payable, net <i>(Note 4)</i>	45,791,924
Total liabilities	<u>54,766,224</u>

Net assets:

Without donor restrictions – undesignated	85,767,162
Without donor restrictions – board designated	1,000,000
Total without donor restrictions	<u>86,767,162</u>
With donor restrictions <i>(Note 5)</i>	66,036,129
Total net assets	<u>152,803,291</u>
Total liabilities and net assets	<u>\$ 207,569,515</u>

See accompanying notes.

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidated Statement of Activities

Year Ended March 31, 2020

	Without Donor Restrictions	With Donor Restrictions	Total
Public support and revenue:			
Restricted investment funds, sponsorships, and race entry fees	\$ 104,681,256	\$ 25,607,336	\$ 130,288,592
Contributed goods and services <i>(Note 1)</i>	77,710,585	2,190,250	79,900,835
Less direct benefits to donors and sponsors	(14,295,715)	—	(14,295,715)
	<u>168,096,126</u>	<u>27,797,586</u>	<u>195,893,712</u>
Interest and dividends	5,318,450	—	5,318,450
Net realized gains on investments	1,320,989	—	1,320,989
Change in net unrealized losses on investments	(20,122,691)	—	(20,122,691)
Other	648,191	—	648,191
Net assets released from restrictions: <i>(Note 5)</i>			
Expiration of time restrictions	17,911,080	(17,911,080)	—
Satisfaction of program restrictions	9,722,670	(9,722,670)	—
Total net public support and revenue	<u>182,894,815</u>	<u>163,836</u>	<u>183,058,651</u>
Expenses:			
Program services:			
Education and patient services	106,546,225	—	106,546,225
Research	5,473,057	—	5,473,057
Treatment services	5,287,450	—	5,287,450
Health screening services	3,777,572	—	3,777,572
Total program services	<u>121,084,304</u>	<u>—</u>	<u>121,084,304</u>
Supporting services:			
Fundraising costs	42,598,400	—	42,598,400
General and administrative	30,978,821	—	30,978,821
Total supporting services	<u>73,577,221</u>	<u>—</u>	<u>73,577,221</u>
Total expenses	<u>194,661,525</u>	<u>—</u>	<u>194,661,525</u>
Change in net assets	(11,766,710)	163,836	(11,602,874)
Net assets at beginning of year	98,533,872	65,872,293	164,406,165
Net assets at end of year	<u>\$ 86,767,162</u>	<u>\$ 66,036,129</u>	<u>\$ 152,803,291</u>

See accompanying notes.

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidated Statement of Cash Flows

Year Ended March 31, 2020

Operating activities

Change in net assets	\$ (11,602,874)
Adjustments to reconcile change in net assets to net cash used in operating activities:	
Depreciation and amortization	468,763
Change in net unrealized losses on investments	20,122,691
Decrease in receivables, net	6,337,031
Increase in prepaid expenses and other assets	(165,225)
Decrease in accounts payable, accrued expenses, and other payables	(702,146)
Decrease in deferred revenue and rent	(295,949)
Decrease in grants payable, net	(39,009,427)
Net cash used in operating activities	<u>(24,847,136)</u>

Investing activities

Purchases of property and equipment	(279,846)
Purchases of investments	(16,399,890)
Sales and maturities of investments	<u>35,094,043</u>
Net cash provided by investing activities	<u>18,414,307</u>

Net decrease in cash, cash equivalents, and restricted cash	(6,432,829)
Cash, cash equivalents, and restricted cash at beginning of year	<u>68,889,183</u>
Cash, cash equivalents, and restricted cash at end of year	<u>\$ 62,456,354</u>

See accompanying notes.

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidated Statement of Functional Expenses

Year Ended March 31, 2020

	Program Services				Supporting Services				
	Education and Patient Services	Research	Treatment Services	Health Screening Services	Fundraising Costs		General and Administrative		Total
					Race-Walk Events and 3-Day	Other Fundraising	Affiliate Relations	Other	
Marketing and communications (primarily contributed services)	\$ 48,905,892	\$ 157,489	\$ 107,208	\$ 84,985	\$ 15,991,674	\$ 1,794,922	\$ 2,550	\$ 13,721,100	\$ 80,765,820
Salaries and benefits	22,798,183	3,338,960	1,688,173	1,112,081	855,801	8,544,402	1,429,296	9,364,092	49,130,988
Supplies	4,669,274	3,494	4,257	3,439	69,595	2,913,517	4,715	118,501	7,786,792
Postage and shipping	3,173,122	6,481	1,026	2,610	156,364	2,096,621	129	37,946	5,474,299
Occupancy	2,211,382	124	29,015	18,691	443,864	288,858	—	1,793,121	4,785,055
Equipment rental and maintenance	3,123,360	204,434	67,831	52,794	495,767	919,744	23,216	914,473	5,801,619
Conferences, conventions, and meetings	986,035	31,644	26,270	18,331	14,092	67,604	3,084	78,528	1,225,588
Printing and publications	753,153	19,908	10,067	4,154	476,437	391,569	1,060	81,492	1,737,840
Grants and direct services	2,391,406	651,512	3,026,206	2,260,824	—	—	—	—	8,329,948
Professional fees	9,279,830	513,257	262,986	174,228	1,662,253	1,606,679	14,934	2,132,571	15,646,738
Travel	1,392,790	323,165	41,250	26,553	176,495	270,708	77,432	158,843	2,467,236
Taxes	14,798	2,748	2,631	70	11,800	21,666	—	15,070	68,783
Event production	5,074,108	72,355	1,567	1,242	1,051,213	207,655	757	33,867	6,442,764
Service fees	581,044	20,400	5,001	7,421	1,311,511	211,896	—	394,839	2,532,112
Telephone and internet fees	335,779	1,045	5,727	7,116	13,542	50,808	28	171,495	585,540
Depreciation and amortization	122,994	14,008	—	—	6,050	90,250	37,360	198,101	468,763
Miscellaneous	733,075	112,033	8,235	3,033	27,154	357,889	24,323	145,898	1,411,640
Total expenses before direct benefits to donors and sponsors	106,546,225	5,473,057	5,287,450	3,777,572	22,763,612	19,834,788	1,618,884	29,359,937	194,661,525
Direct benefits to donors and sponsors	—	—	—	—	12,358,948	1,911,057	—	25,710	14,295,715
Total expenses	<u>\$ 106,546,225</u>	<u>\$ 5,473,057</u>	<u>\$ 5,287,450</u>	<u>\$ 3,777,572</u>	<u>\$ 35,122,560</u>	<u>\$ 21,745,845</u>	<u>\$ 1,618,884</u>	<u>\$ 29,385,647</u>	<u>\$ 208,957,240</u>

See accompanying notes.

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Notes to Consolidated Financial Statements

March 31, 2020

1. General Information and Summary of Significant Accounting Policies

General Information

The Susan G. Komen Breast Cancer Foundation, Inc. doing business as Susan G. Komen and Affiliates (the Organization), a Texas not-for-profit corporation, was incorporated in July 1982. The primary mission of the Organization is to eradicate breast cancer as a life-threatening disease by advancing research, education, screening, and treatment. Research advancement is achieved through relationships with medical and cancer centers throughout the United States, as well as internationally. Treatment and screening programs, primarily funded through the Organization's Affiliates, produce affordable treatment and screening for the medically underserved and other target populations. The Organization's reach has expanded tremendously since its inception, due in large part to the Komen Race for the Cure[®] Series (the RFTC Series), the More than Pink Walk Series (the MTP Walk Series), and other fundraising programs and events, as well as the Organization's many donors, corporate partners, and educational initiatives and materials. As a result of this heightened awareness of breast cancer, millions have received the life-saving message of early detection.

The accompanying consolidated financial statements of the Organization include the activity of the Organization's international headquarters and 61 Affiliates in 2020. All significant intercompany accounts have been eliminated in the accompanying consolidated financial statements.

The RFTC Series and MTP Walk Series, a series of 5K and one-mile walk/runs, were held in 103 cities across the United States during 2020 and are a significant source of the Organization's revenues. The Breast Cancer 3-Day Series (The 3-Day Series), a series of 60-mile walks over a three-day period, was held in seven cities across the United States in 2020.

Up to approximately 75% of the net proceeds generated by the Affiliates are used to fund breast cancer education, treatment, and screening projects within local communities. The remaining 25% is used to fund breast cancer research and project grants on a national level.

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Notes to Consolidated Financial Statements (continued)

1. General Information and Summary of Significant Accounting Policies (continued)

The following Affiliates are included in the accompanying consolidated financial statements:

Arkansas	Greater Detroit	Maryland	Peoria Memorial
Austin	Greater Evansville	Memphis Mid-South	Philadelphia
Baton Rouge	Greater Kansas City	Miami – Ft. Lauderdale	Pittsburgh
Boise	Greater Nashville	Milwaukee	Puget Sound
Central & South Jersey	Greater New York City	Minnesota	Sacramento Valley
Charlotte	Greater Richmond	NC Triangle	San Antonio
Chicagoland Area	Greater Roanoke	Nebraska	San Diego
Coastal Georgia	Hawaii	New Orleans	San Francisco Bay Area
Columbus	Houston	North Central Alabama	South Florida
Connecticut	Indianapolis	North Jersey	St. Louis
Dallas County	Inland Empire	North Texas	Tarrant County
Denver Metropolitan	Knoxville	Northeast Ohio	Tulsa
Des Moines	Las Vegas	Northwest Ohio	Western New York
Grand Rapids	Los Angeles County	Orange County	
Greater Atlanta	Louisville	Oregon & SW Washington	
Greater Cincinnati	Lowcountry (Charleston)	Ozark	

International Affiliates of the Organization operate in Italy and Puerto Rico under two separate international Affiliate agreements. The financial statements of the two international Affiliates are not included in the accompanying consolidated financial statements since the Organization does not currently exercise economic or board-controlling interests over either of these Affiliates.

Basis of Presentation

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting, in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for not-for-profit organizations. Under these provisions, net assets, revenues, gains, and losses are classified based on the existence or absence of donor-imposed restrictions. Expenses are classified as without donor restrictions. Accordingly, net assets of the Organization and changes therein are classified and reported as follows:

- *Net assets without donor restrictions, undesignated* – Net assets that are not subject to donor-imposed stipulations.

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Notes to Consolidated Financial Statements (continued)

1. General Information and Summary of Significant Accounting Policies (continued)

- *Net assets without donor restrictions, board-designated* – Board-designated net assets without donor restrictions are those designated by the Board of Directors as restricted for mission expenditures.
- *Net assets with donor restrictions, program or time* – Net assets subject to donor-imposed stipulations that will be met either by actions of the Organization and/or the passage of time. When a restriction is satisfied or expires, restricted net assets are reclassified to net assets without donor restrictions and reported on the consolidated statement of activities as net assets released from restrictions. Contributions received with donor-imposed restrictions that are met in the same year as contributions are received are reported as revenues without donor restrictions.
- *Net assets with donor restrictions, perpetual in nature* – Net assets subject to donor-imposed stipulations for which the corpus is maintained permanently by the Organization. Generally, the donors of these assets permit the Organization to use all or part of the income earned on related investments for general or specific purposes.

The Organization prepares consolidated statements of financial position, activities, cash flows, and functional expenses as the required financial statements for not-for-profit organizations.

The Organization reports gifts of property and equipment as undesignated support unless explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as donor restricted revenue. Absent explicit donor stipulations about how long those long-lived assets must be maintained, the Organization reports expirations of donor restrictions when the donated or acquired long-lived assets are placed in service.

Contributed Goods and Services

Total contributed goods and services for the year ended March 31, 2020, were approximately \$79,901,000 and primarily relate to local television, radio, and newspaper advertising for the MTP Walk Series and the RFTC Series events. Contributed materials and equipment are reported as contributions in the accompanying consolidated financial statements at their estimated fair values

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Notes to Consolidated Financial Statements (continued)

1. General Information and Summary of Significant Accounting Policies (continued)

at date of receipt. Contributed services are reported in the accompanying consolidated financial statements at the fair value of the services received. The contribution of services is recognized if the services received (a) create or enhance nonfinancial assets or (b) require specialized skills that are provided by individuals possessing those skills that would typically need to be purchased if not provided by donation.

In addition, the Organization receives services from a large number of volunteers who give significant amounts of their time to the Organization's programs, fundraising campaigns, and management. No amounts have been reflected for these types of donated services, as they do not meet the criteria outlined above.

Contributed goods and services for the year ended March 31, 2020, are detailed in the table below:

	Amounts per Consolidated Financial Statements	Value of In-Kind Contributed Goods and Services	Net Without In-Kind
Public support and revenue	\$ 197,354,366	\$ 79,900,835	\$ 117,453,531
Less:			
Event direct costs	(14,295,715)	(5,981,720)	(8,313,995)
Net public support and revenue	183,058,651	73,919,115	109,139,536
Expenses:			
Program services	121,084,304	47,331,918	73,752,386
Supporting services	73,577,221	31,579,661	41,997,560
Total expenses	194,661,525	78,911,579	115,749,946
Change in net assets	\$ (11,602,874)	\$ (4,992,464)	\$ (6,610,410)
Program services as a percentage of total expense	62%	60%	64%

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Notes to Consolidated Financial Statements (continued)

1. General Information and Summary of Significant Accounting Policies (continued)

Contributions

Contributions, including unconditional promises to give, are recorded when received or pledged. All contributions are available for undesignated use unless specifically restricted by the donor. Conditional promises to give are recognized when the conditions on which they depend are substantially met.

Cash, Cash Equivalents, and Restricted Cash

Cash and cash equivalents consist of cash on hand and all highly liquid investments with a remaining maturity of three months or less when purchased. Restricted cash represents amounts required to be utilized for specific programs and will be released upon program completion.

Cash and cash equivalents	\$ 50,908,397
Restricted cash	<u>11,547,957</u>
Total cash, cash equivalents, and restricted cash shown on the statement of cash flows	<u>\$ 62,456,354</u>

Investments and Investment Income

Investments in equity securities with readily determinable fair values and all investments in debt securities are reported at fair value. The Organization has diversified its investments to include defensive equity fund investments that are reported at the net asset value as a practical expedient.

Investment income includes dividends and interest and is recognized as revenue in the period in which it is earned. The amounts are reported as an increase in undesignated net assets without donor restrictions unless otherwise restricted by the donor. Realized and unrealized gains and losses on investments are classified and recorded as increases or decreases in undesignated net assets without donor restrictions, unless otherwise restricted by the donor.

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Notes to Consolidated Financial Statements (continued)

1. General Information and Summary of Significant Accounting Policies (continued)

Property, Equipment, and Intangible Assets

Purchased property, equipment, and intangible assets are carried at cost. Donated property, equipment, and intangible assets are recorded at market value at the date of donation. The Organization capitalizes all expenditures for property, equipment, and intangible assets in excess of approximately \$10,000, which includes computers, software, office equipment, furniture, fixtures, leasehold improvements, and intangible assets.

Property, equipment, and intangible assets are depreciated on a straight-line basis over the following periods:

Furniture and fixtures	5–7 years
Equipment	3–5 years
Software	3–5 years
Leasehold improvements	Estimated life of the asset or the lease term (whichever is shorter)
Identifiable intangible assets	3–5 years

Property, equipment, and intangible assets and the related accumulated depreciation and amortization are as follows:

Equipment	\$ 2,806,659
Furniture and fixtures	1,131,669
Leasehold improvements	1,239,945
Software	2,897,068
Identifiable intangible assets	2,839,583
Fixed assets in process	153,342
Total property, equipment, and intangible assets	11,068,266
Accumulated depreciation and amortization	(10,074,857)
Net property, equipment, and intangible assets	<u>\$ 993,409</u>

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Notes to Consolidated Financial Statements (continued)

1. General Information and Summary of Significant Accounting Policies (continued)

As of March 31, 2020, accumulated amortization of intangible assets totaled approximately \$2,781,000.

As of March 31, 2020, the aggregate depreciation and amortization expense for the next five fiscal years is approximately \$350,000.

Inventories

Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method. Inventories consist of educational materials and branded merchandise held for use in program services and sales to unrelated parties. Inventories are included in prepaid expenses and other assets on the accompanying consolidated statement of financial position and total approximately \$215,000 as of March 31, 2020.

Market and Credit Risk Concentrations

The Organization's investments do not have a significant concentration of credit or market risk within any industry, specific institution, or group of investments. The Organization splits funds between multiple accounts to manage risk and has investments in private and defensive equity funds.

The Organization is the beneficiary of a grant of equity securities in a privately held fund. This grant was valued by a third-party valuation firm at the date of award. As the Organization is a minority nonvoting shareholder, there is some market risk associated with this investment.

Deferred Revenue

Resources received in exchange transactions are recognized as deferred revenue to the extent that the earnings process has not been completed. These amounts primarily consist of entry fees for The 3-Day Series, RFTC Series, and MTP Walk Series events. These resources are recorded as undesignated revenues when the related obligations have been satisfied.

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Notes to Consolidated Financial Statements (continued)

1. General Information and Summary of Significant Accounting Policies (continued)

Functional Allocation of Expenses

The costs of providing the Organization's various programs and other activities have been summarized on a functional basis. Expenses directly attributable to a specific functional area of the Organization are reported as expenses of those functional areas. The Organization has adopted Accounting Standards Update (ASU) 2016-14, *Not-for-Profit Entities (Topic 958): Presentation of Financial Statements of Not-for-Profit Entities*. Expenses that benefit multiple functional areas require allocation on a reasonable basis that consistently includes expenses for information technology, facilities, legal, marketing and communications, and office of the president and CEO departments. These departmental expenses were allocated based on time and cost studies of where efforts were made and square footage usage. Management and general expenses such as accounting or human resources are no longer able to be allocated to program expense.

Advertising Expenses

The Organization recorded advertising expenses of approximately \$80,766,000 for the year ended March 31, 2020, which are included in marketing and communications on the accompanying consolidated statement of functional expenses. The majority of advertising was contributed. Other purchased advertising cost primarily relates to The 3-Day Series, RFTC Series events, and MTP Walk Series events.

Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures, such as the allowance for doubtful accounts and accounts receivable related to trusts where the Organization is the beneficiary. Accordingly, actual results could differ from those estimates.

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Notes to Consolidated Financial Statements (continued)

1. General Information and Summary of Significant Accounting Policies (continued)

Subsequent Events

The Organization defines subsequent events as events or transactions that occur after the consolidated statement of financial position date, but before the consolidated financial statements are issued or available to be issued. Subsequent events are recognized in two categories: (1) recognized subsequent events, which provide additional evidence about conditions that existed at the consolidated statement of financial position date, and (2) non-recognized subsequent events, which provide evidence about conditions that did not exist as of the consolidated statement of financial position date but arose after that date. Recognized subsequent events are required to be disclosed. Management has evaluated subsequent events through September 14, 2020, which is the date the accompanying consolidated financial statements were available to be issued, and no events have occurred from the consolidated statement of financial position date that would affect the accompanying consolidated financial statements.

New and Pending Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (FASB) issued ASU 2014-09, enacting Accounting Standards Codification (ASC) 606, *Revenue from Contracts with Customers*, to clarify the principles for recognizing revenue and to improve financial reporting by creating common revenue recognition guidance for U.S. GAAP and International Financial Reporting Standards. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 is now effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. Early adoption is permitted. The Organization has evaluated the guidance in ASU 2014-09 and has determined the impact will not result in material changes to its consolidated financial statements.

In November 2016, the FASB issued ASU 2016-18, *Statement of Cash Flows (Topic 230): Restricted Cash*, as an update to ASC 230, *Statement of Cash Flows*. This update required that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The updated guidance is effective for annual periods beginning after December 15, 2018, for nonpublic business entities, and interim periods within those fiscal years. The updated guidance has resulted in a change on the cash flow statement to include restricted cash and restricted cash equivalents.

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Notes to Consolidated Financial Statements (continued)

1. General Information and Summary of Significant Accounting Policies (continued)

In June 2018, the FASB issued ASU 2018-08, *Not-for-Profit Entities (Topic 958): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made*, to clarify the scope and the accounting guidance for contributions received and made, primarily by not-for-profit organizations. The update is effective for annual reporting periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2018. Adoption of ASU 2018-08 did not have a material impact on the Organization's consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, enacting ASC 842, *Leases*, which requires a lessee to recognize a right-of-use asset and a lease liability for both operating and finance leases, whereas previous U.S. GAAP required the asset and liability to be recognized only for capital leases. The amendment also requires qualitative and specific quantitative disclosures. ASU 2016-02 is effective for the Organization with fiscal years beginning after December 15, 2020, with early adoption permitted. The Organization is evaluating the guidance of ASU 2016-02 and the impact that the adoption of this update will have on its consolidated financial statements.

2. Fair Value Measurements

At March 31, 2020, the Organization's financial instruments included cash and cash equivalents, receivables, investments, accounts payable, accrued expenses, and grants payable. The carrying amounts reported on the accompanying consolidated statement of financial position for these financial instruments approximate their fair values.

Investments are recorded and disclosed on a three-level hierarchy. The valuation hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

- Level 1 – Inputs to the valuation methodology are quoted prices for identical assets and liabilities in active markets.
- Level 2 – Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Notes to Consolidated Financial Statements (continued)

2. Fair Value Measurements (continued)

- Level 3 – Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

A financial instrument’s categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. In an effort to deliver long-term returns that are competitive with equity investments, but with less volatility, the Organization utilizes a diversified portfolio of investments consisting primarily of equity and bond investments that have a balance of long- and short-term horizons and has invested a modest allocation in defensive equity funds.

The Organization incurred investment expenses of approximately \$201,000 in the fiscal year ended March 31, 2020, which are netted against net realized gains on investments on the accompanying consolidated statement of activities. Investments at March 31, 2020, were composed of the following:

	<u>Cost</u>	<u>Fair Value</u>
Domestic equities	\$ 19,847,128	\$ 15,299,727
International equities	25,035,411	20,907,246
Fixed-income funds	23,565,300	23,526,800
Corporate bonds	343,182	320,078
Government bonds	284,545	327,121
Certificates of deposit	3,595,568	3,599,210
Private equity fund	36,477,000	36,477,000
Defensive equity funds	15,669,430	15,404,153
Total	<u>\$ 124,817,564</u>	<u>\$ 115,861,335</u>

The Organization uses a practical expedient for the estimation of the value of investments that do not have a readily determinable fair value. The practical expedient used by the Organization for its alternative investments is the net asset value per share, or its equivalent. Valuations provided by the defensive equity fund and private equity fund management consider variables such as the financial performance of underlying equity positions, recent sales prices of underlying investments, and other pertinent information. As of March 31, 2020, the defensive equity funds were valued at \$15,404,153. As of March 31, 2020, the private equity fund was valued at \$36,477,000.

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Notes to Consolidated Financial Statements (continued)

2. Fair Value Measurements (continued)

	Balance March 31, 2020	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Other Observable Inputs (Level 3)
Domestic equities	\$ 15,299,727	\$ 15,299,727	\$ —	\$ —
International equities	20,907,246	20,907,246	—	—
Fixed-income funds	23,526,800	23,526,800	—	—
Corporate bonds	320,078	—	320,078	—
Government bonds	327,121	327,121	—	—
Certificates of deposit	3,599,210	—	3,599,210	—
	<u>63,980,182</u>	<u>\$ 60,060,894</u>	<u>\$ 3,919,288</u>	<u>\$ —</u>
Investments reported using net asset value per share:				
Private equity fund ^(a)	36,477,000			
Defensive equity funds	15,404,153			
Fair value of investments	<u>\$ 115,861,335</u>			

^(a)The Organization may not request to redeem shares in this fund. Based upon the fund strategy, distributions will be made starting no later than calendar year 2019 and ending with a final distribution no later than calendar year 2023.

3. Receivables

Net receivables were approximately \$25,626,000 at March 31, 2020. Receivables that are expected to be collected within one year are recorded at net realizable value. Receivables that are expected to be collected in future years are recorded at the present value of their estimated future cash flows. The discount rates used range from 0.17% to 2.40% at March 31, 2020. The discount as of March 31, 2020, was approximately \$321,000. The allowance for doubtful accounts was approximately \$443,000 as of March 31, 2020.

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Notes to Consolidated Financial Statements (continued)

3. Receivables (continued)

The Organization maintains an allowance for doubtful accounts for estimated credit losses resulting from collection risks, including the inability of donors to make required payments under contractual agreements. The allowance for doubtful accounts is reported as a reduction of accounts receivable on the consolidated statement of financial position. The adequacy of this allowance is determined by evaluating historical delinquency and write-off trends, specific known collection risks, historical payment trends, current economic conditions, and the impact of such conditions on the donors' liquidity and overall financial condition.

Receivables, net, as of March 31, 2020, are as follows:

2021	\$ 8,709,877
2022	6,395,790
2023	4,096,066
Thereafter	<u>6,745,000</u>
Total accounts receivable, net of allowances	25,946,733
Less unamortized discount	<u>(321,170)</u>
Accounts receivable, net	<u>\$ 25,625,563</u>

The RFTC Series and MTP Walk Series and other event receivables were approximately \$19,082,000 at March 31, 2020. These receivables primarily represent promises to give from national and local sponsors who committed support prior to March 31 each year.

Unconditional promises to give by donors net of allowances and discounts of approximately \$6,814,000 at March 31, 2020, are expected to be received by the Organization over periods ranging from one to three years, with the majority of the balances due within one year.

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Notes to Consolidated Financial Statements (continued)

4. Grants Payable

As of March 31, 2020, the Organization made grants to various medical and cancer centers for research; education; and patient support, screening, and treatment. These agreements are subject to periodic reporting and compliance requirements and can be rescinded by the Organization for breach. Grants payable in more than one year are discounted to their present values as of March 31, 2020, at rates ranging from 0.17% to 2.48%. The grants payable at March 31, 2020, are scheduled for payment in the following fiscal years:

2021	\$ 28,819,020
2022	12,430,392
2023	4,590,649
2024	413,388
Total grants payable	<u>46,253,449</u>
Less unamortized discount	(461,525)
Grants payable, net	<u><u>\$ 45,791,924</u></u>

The Organization generally funds its obligations under these arrangements from cash flows from operations and available cash and cash equivalent and investment balances.

5. Net Assets

Net assets with donor restrictions as of March 31, 2020, are categorized as follows:

Education and patient support programs	\$ 27,415,266
Research programs	15,666,791
Screening and treatment programs	730,541
Time restrictions	21,898,531
Perpetual in nature	325,000
	<u><u>\$ 66,036,129</u></u>

Net assets with donor restrictions – perpetual in nature represent endowed gifts to be held in perpetuity, with the investment income to be used for breast cancer research fellowships, breast cancer educational programs, and research awards.

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Notes to Consolidated Financial Statements (continued)

6. Joint Costs

The accompanying consolidated statement of activities includes joint activities (activities benefiting multiple programs and/or supporting services) that include fundraising. The joint costs were primarily for the RFTC Series, MTP Walk Series, and The 3-Day Series; informational materials; a website that includes fundraising; and direct mail campaigns. The cost of conducting those joint activities was allocated as follows in the fiscal year ended March 31, 2020:

Research	\$ 1,680,052
Public health education, treatment, and screening	29,081,024
General and administrative	772,172
Fundraising	37,751,829
	<u>\$ 69,285,077</u>

7. Leases

The Organization has operating lease agreements for office space and associated common area maintenance and utilities. Total rent expense was approximately \$4,249,000 for the fiscal year ended March 31, 2020.

Future annual minimum lease payments due under noncancelable operating leases as of March 31, 2020, are as follows:

2021	\$ 2,781,332
2022	2,306,349
2023	1,786,671
2024	1,353,045
2025	792,147
Thereafter	168,929
Total future annual minimum lease payments	<u>\$ 9,188,473</u>

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Notes to Consolidated Financial Statements (continued)

8. Federal Income Taxes

The Organization is a tax-exempt entity under Internal Revenue Code (the Code) Section 501(a) of the U.S. Tax Code as an organization described in Section 501(c)(3) under a determination letter issued by the Internal Revenue Service. The Affiliates of the Organization have a separate group determination letter, under the umbrella of the Organization's exemption, recognizing their exempt status under Section 501(a) of the Code. Furthermore, the Organization has been classified as an organization that is not a private organization under Section 509(a) of the Code, and as such, contributions to the Organization qualify for deduction as charitable contributions.

The Organization is subject to a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There were no uncertain tax positions recorded in the consolidated financial statements at March 31, 2020.

9. Retirement Plans

The Organization has a defined contribution retirement plan under the provisions of Section 403(b) of the Code (the 403(b) Plan). The Organization can match employee contributions up to 6% of employees' annual salary. All employees are eligible to make deferrals immediately. However, participants are not eligible to receive the employer matching contribution until after one year of continuous employment. The 403(b) Plan expense was approximately \$927,000 for the year ended March 31, 2020.

The Organization has a nonqualified deferred compensation plan subject to the provisions of Section 457 of the Code (the 457 Plan). The 457 Plan is maintained primarily for certain members of management. No significant changes occurred during the year.

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Notes to Consolidated Financial Statements (continued)

10. Liquidity

The Organization's financial assets available within one year of the consolidated statement of financial position date for general expenditure are as follows:

Total assets at year-end	\$ 207,569,515
Less:	
Private equity fund	(36,477,000)
Restricted by donors with purpose restrictions	(11,547,957)
Grants payable within a year	(28,819,020)
Contributions receivable due in more than one year, net	(16,915,686)
In-kind receivables	(2,289,192)
Prepaid expenses and other assets	(2,632,854)
Property, equipment, and intangible assets, net	(993,409)
Board-designated restricted fund	(1,000,000)
Financial assets available at year-end for current use	<u>\$ 106,894,397</u>

The Organization has substantial support by restricted contributions. Because a donor's restriction requires resources to be used in a particular manner or in a future period, the Organization must maintain sufficient resources to meet those responsibilities to its donors. Thus, financial assets may not be available for general expenditure within one year. Investments within the defensive equity fund have a 30-day redemption notice with no lockout provisions. The Organization maintains a policy of structuring its financial assets to be available as its general expenditures, liabilities, and other obligations come due.

Supplementary Information

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Statement of Financial Position by Affiliate

March 31, 2020

	Arkansas	Austin	Baton Rouge	Boise	Central & South Jersey	Charlotte
Assets						
Cash, cash equivalents, and restricted cash	\$ 638,781	\$ 933,077	\$ 414,454	\$ 277,367	\$ 1,094,134	\$ 397,593
Investments	317,256	-	-	-	-	930,236
Receivables, net	64,240	164,920	28,229	90,513	16,775	39,038
Prepaid expenses and other assets	3,103	31,129	3,420	1,402	361	33,860
Property, equipment, and intangible assets, net	-	-	-	-	-	-
Total assets	<u>\$ 1,023,380</u>	<u>\$ 1,129,126</u>	<u>\$ 446,103</u>	<u>\$ 369,282</u>	<u>\$ 1,111,270</u>	<u>\$ 1,400,727</u>
Liabilities						
Accounts payable, accrued expenses, and other payables	\$ 35,911	\$ 43,177	\$ 18,942	\$ 9,640	\$ 31,409	\$ 41,662
Deferred revenue and rent	17,786	3,299	18,739	27,056	3,124	-
Grants payable, net	13,275	-	-	56,911	-	215,418
Intercompany payable, net	30,487	92,560	50,997	33,213	140,500	83,132
Total liabilities	<u>97,459</u>	<u>139,036</u>	<u>88,678</u>	<u>126,820</u>	<u>175,033</u>	<u>340,212</u>
Total net assets	925,921	990,090	357,425	242,462	936,237	1,060,515
Total liabilities and net assets	<u>\$ 1,023,380</u>	<u>\$ 1,129,126</u>	<u>\$ 446,103</u>	<u>\$ 369,282</u>	<u>\$ 1,111,270</u>	<u>\$ 1,400,727</u>

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Statement of Financial Position by Affiliate (continued)

	Chicagoland Area	Coastal Georgia	Columbus	Connecticut	Dallas County	Denver Metropolitan
Assets						
Cash, cash equivalents, and restricted cash	\$ 1,949,682	\$ 702,588	\$ 1,866,500	\$ 824,458	\$ 984,066	\$ 913,818
Investments	–	19,355	–	–	751,105	835,384
Receivables, net	69,769	60,630	620,193	284,531	78,110	22,427
Prepaid expenses and other assets	37,216	796	873	16,673	–	12,861
Property, equipment, and intangible assets, net	–	–	–	–	–	–
Total assets	<u>\$ 2,056,667</u>	<u>\$ 783,369</u>	<u>\$ 2,487,566</u>	<u>\$ 1,125,662</u>	<u>\$ 1,813,281</u>	<u>\$ 1,784,490</u>
Liabilities						
Accounts payable, accrued expenses, and other payables	\$ 89,858	\$ 11,716	\$ 120,740	\$ 48,980	\$ 26,496	\$ 50,390
Deferred revenue and rent	8,753	22,114	39,742	12,136	100	–
Grants payable, net	–	114,819	–	29,800	810,698	–
Intercompany payable, net	226,513	101,752	157,465	336,082	83,891	45,386
Total liabilities	<u>325,124</u>	<u>250,401</u>	<u>317,947</u>	<u>426,998</u>	<u>921,185</u>	<u>95,776</u>
Total net assets	1,731,543	532,968	2,169,619	698,664	892,096	1,688,714
Total liabilities and net assets	<u>\$ 2,056,667</u>	<u>\$ 783,369</u>	<u>\$ 2,487,566</u>	<u>\$ 1,125,662</u>	<u>\$ 1,813,281</u>	<u>\$ 1,784,490</u>

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Statement of Financial Position by Affiliate (continued)

	Des Moines	Grand Rapids	Greater Atlanta	Greater Cincinnati	Greater Detroit	Greater Evansville
Assets						
Cash, cash equivalents, and restricted cash	\$ 609,628	\$ 389,004	\$ 2,275,869	\$ 300,381	\$ 963,296	\$ 178,366
Investments	89,052	—	—	—	—	—
Receivables, net	137,993	126,681	150,254	3,696	91,213	628
Prepaid expenses and other assets	10,543	5,560	7,197	—	20,301	2,963
Property, equipment, and intangible assets, net	—	—	23,064	—	—	—
Total assets	<u>\$ 847,216</u>	<u>\$ 521,245</u>	<u>\$ 2,456,384</u>	<u>\$ 304,077</u>	<u>\$ 1,074,810</u>	<u>\$ 181,957</u>
Liabilities						
Accounts payable, accrued expenses, and other payables	\$ 22,869	\$ 22,823	\$ 82,145	\$ 14,704	\$ 19,535	\$ 8,708
Deferred revenue and rent	13,150	1,173	19,601	1,452	45,183	—
Grants payable, net	—	—	—	—	310,753	12,118
Intercompany payable, net	13,773	77,599	283,607	88,925	25,165	4,700
Total liabilities	<u>49,792</u>	<u>101,595</u>	<u>385,353</u>	<u>105,081</u>	<u>400,636</u>	<u>25,526</u>
Total net assets	797,424	419,650	2,071,031	198,996	674,174	156,431
Total liabilities and net assets	<u>\$ 847,216</u>	<u>\$ 521,245</u>	<u>\$ 2,456,384</u>	<u>\$ 304,077</u>	<u>\$ 1,074,810</u>	<u>\$ 181,957</u>

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Statement of Financial Position by Affiliate (continued)

	Greater Kansas City	Greater Nashville	Greater New York City	Greater Richmond	Greater Roanoke	Hawaii
Assets						
Cash, cash equivalents, and restricted cash	\$ 276,229	\$ 663,028	\$ 1,814,233	\$ 497,745	\$ 652,224	\$ 429,641
Investments	276,451	–	–	52,854	–	–
Receivables, net	30,715	105,550	482,068	117,176	205,899	389
Prepaid expenses and other assets	–	3,555	268,086	–	2,638	31,398
Property, equipment, and intangible assets, net	–	–	29,996	–	–	–
Total assets	<u>\$ 583,395</u>	<u>\$ 772,133</u>	<u>\$ 2,594,383</u>	<u>\$ 667,775</u>	<u>\$ 860,761</u>	<u>\$ 461,428</u>
Liabilities						
Accounts payable, accrued expenses, and other payables	\$ 39,678	\$ 36,180	\$ 125,508	\$ 14,965	\$ 15,748	\$ 7,868
Deferred revenue and rent	–	5,910	24,949	11,287	11,193	53,900
Grants payable, net	7,915	2,032	288,375	–	–	–
Intercompany payable, net	5,554	58,047	182,709	102,844	105,142	33,905
Total liabilities	<u>53,147</u>	<u>102,169</u>	<u>621,541</u>	<u>129,096</u>	<u>132,083</u>	<u>95,673</u>
Total net assets	530,248	669,964	1,972,842	538,679	728,678	365,755
Total liabilities and net assets	<u>\$ 583,395</u>	<u>\$ 772,133</u>	<u>\$ 2,594,383</u>	<u>\$ 667,775</u>	<u>\$ 860,761</u>	<u>\$ 461,428</u>

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Statement of Financial Position by Affiliate (continued)

	Houston	Indianapolis	Inland Empire	Knoxville	Las Vegas	Los Angeles County
Assets						
Cash, cash equivalents, and restricted cash	\$ 700,214	\$ 502,375	\$ 613,763	\$ 443,688	\$ 345,070	\$ 641,336
Investments	–	775,447	–	–	–	–
Receivables, net	243,940	28,926	32,134	51,862	91,130	243,004
Prepaid expenses and other assets	–	35,166	3,698	–	–	10,375
Property, equipment, and intangible assets, net	45,691	–	–	–	–	–
Total assets	<u>\$ 989,845</u>	<u>\$ 1,341,914</u>	<u>\$ 649,595</u>	<u>\$ 495,550</u>	<u>\$ 436,200</u>	<u>\$ 894,715</u>
Liabilities						
Accounts payable, accrued expenses, and other payables	\$ 44,686	\$ 50,031	\$ 15,052	\$ 13,733	\$ 5,245	\$ 106,670
Deferred revenue and rent	–	60,442	–	6,217	2,998	–
Grants payable, net	20,000	99,193	–	–	101,837	–
Intercompany payable, net	275,332	29,832	36,140	126,523	51,344	171,770
Total liabilities	<u>340,018</u>	<u>239,498</u>	<u>51,192</u>	<u>146,473</u>	<u>161,424</u>	<u>278,440</u>
Total net assets	649,827	1,102,416	598,403	349,077	274,776	616,275
Total liabilities and net assets	<u>\$ 989,845</u>	<u>\$ 1,341,914</u>	<u>\$ 649,595</u>	<u>\$ 495,550</u>	<u>\$ 436,200</u>	<u>\$ 894,715</u>

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Statement of Financial Position by Affiliate (continued)

	Louisville	Lowcountry (Charleston)	Maryland	Memphis Mid-South	Miami – Ft. Lauderdale	Milwaukee
Assets						
Cash, cash equivalents, and restricted cash	\$ 527,954	\$ 380,092	\$ 321,579	\$ 686,153	\$ 936,733	\$ 1,276,236
Investments	–	–	96,862	–	–	–
Receivables, net	215	2,528	220,286	33,030	39,284	97,533
Prepaid expenses and other assets	9,444	1,433	1,000	–	4,135	11,702
Property, equipment, and intangible assets, net	–	–	–	–	–	–
Total assets	<u>\$ 537,613</u>	<u>\$ 384,053</u>	<u>\$ 639,727</u>	<u>\$ 719,183</u>	<u>\$ 980,152</u>	<u>\$ 1,385,471</u>
Liabilities						
Accounts payable, accrued expenses, and other payables	\$ 31,625	\$ 21,396	\$ 61,746	\$ 15,706	\$ 7,857	\$ 26,169
Deferred revenue and rent	128	463	585	2,033	60	9,538
Grants payable, net	38,238	–	–	313,827	252,530	–
Intercompany payable, net	14,803	20,775	189,809	20,161	65,174	26,013
Total liabilities	<u>84,794</u>	<u>42,634</u>	<u>252,140</u>	<u>351,727</u>	<u>325,621</u>	<u>61,720</u>
Total net assets	452,819	341,419	387,587	367,456	654,531	1,323,751
Total liabilities and net assets	<u>\$ 537,613</u>	<u>\$ 384,053</u>	<u>\$ 639,727</u>	<u>\$ 719,183</u>	<u>\$ 980,152</u>	<u>\$ 1,385,471</u>

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Statement of Financial Position by Affiliate (continued)

	Minnesota	NC Triangle	Nebraska	New Orleans	North Central Alabama	North Jersey
Assets						
Cash, cash equivalents, and restricted cash	\$ 795,539	\$ 1,006,680	\$ 493,579	\$ 348,540	\$ 372,020	\$ 957,970
Investments	-	-	696,254	-	-	246
Receivables, net	286,004	17,050	223,581	1,775	2,483	157,422
Prepaid expenses and other assets	-	6,638	-	2,342	-	-
Property, equipment, and intangible assets, net	-	-	-	-	-	31,686
Total assets	<u>\$ 1,081,543</u>	<u>\$ 1,030,368</u>	<u>\$ 1,413,414</u>	<u>\$ 352,657</u>	<u>\$ 374,503</u>	<u>\$ 1,147,324</u>
Liabilities						
Accounts payable, accrued expenses, and other payables	\$ 37,361	\$ 34,115	\$ 30,561	\$ 10,270	\$ 19,944	\$ 48,011
Deferred revenue and rent	40,501	40,230	8,720	19,050	2,047	6,232
Grants payable, net	276,075	-	-	-	-	-
Intercompany payable, net	19,802	70,985	49,440	9,026	7,001	81,296
Total liabilities	<u>373,739</u>	<u>145,330</u>	<u>88,721</u>	<u>38,346</u>	<u>28,992</u>	<u>135,539</u>
Total net assets	707,804	885,038	1,324,693	314,311	345,511	1,011,785
Total liabilities and net assets	<u>\$ 1,081,543</u>	<u>\$ 1,030,368</u>	<u>\$ 1,413,414</u>	<u>\$ 352,657</u>	<u>\$ 374,503</u>	<u>\$ 1,147,324</u>

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Statement of Financial Position by Affiliate (continued)

	North Texas	Northeast Ohio	Northwest Ohio	Orange County	Oregon & SW Washington	Ozark
Assets						
Cash, cash equivalents, and restricted cash	\$ 693,751	\$ 384,203	\$ 236,276	\$ 917,685	\$ 375,287	\$ 765,525
Investments	205,886	–	538,546	1,501,210	–	208,452
Receivables, net	148,227	7,122	49,857	430,072	88,687	100,056
Prepaid expenses and other assets	4,001	–	7,500	84,020	5,618	–
Property, equipment, and intangible assets, net	2,395	5,662	–	4,304	9,602	–
Total assets	<u>\$ 1,054,260</u>	<u>\$ 396,987</u>	<u>\$ 832,179</u>	<u>\$ 2,937,291</u>	<u>\$ 479,194</u>	<u>\$ 1,074,033</u>
Liabilities						
Accounts payable, accrued expenses, and other payables	\$ 23,069	\$ 44,664	\$ 34,664	\$ 401,474	\$ 60,345	\$ 19,728
Deferred revenue and rent	13,885	5,697	570	–	6,674	7,300
Grants payable, net	287,827	–	–	316,479	–	467,764
Intercompany payable, net	65,920	26,421	30,613	14,303	42,989	35,737
Total liabilities	<u>390,701</u>	<u>76,782</u>	<u>65,847</u>	<u>732,256</u>	<u>110,008</u>	<u>530,529</u>
Total net assets	663,559	320,205	766,332	2,205,035	369,186	543,504
Total liabilities and net assets	<u>\$ 1,054,260</u>	<u>\$ 396,987</u>	<u>\$ 832,179</u>	<u>\$ 2,937,291</u>	<u>\$ 479,194</u>	<u>\$ 1,074,033</u>

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Statement of Financial Position by Affiliate (continued)

	Peoria Memorial	Philadelphia	Pittsburgh	Puget Sound	Sacramento Valley	San Antonio
Assets						
Cash, cash equivalents, and restricted cash	\$ 1,191,173	\$ 1,917,181	\$ 160,865	\$ 1,081,982	\$ 269,178	\$ 508,424
Investments	250,000	-	1,070,430	-	-	-
Receivables, net	209,861	442,614	212,904	229,191	48,933	118,245
Prepaid expenses and other assets	20,282	15,214	26,898	36,375	8,943	-
Property, equipment, and intangible assets, net	-	20,415	-	-	-	-
Total assets	<u>\$ 1,671,316</u>	<u>\$ 2,395,424</u>	<u>\$ 1,471,097</u>	<u>\$ 1,347,548</u>	<u>\$ 327,054</u>	<u>\$ 626,669</u>
Liabilities						
Accounts payable, accrued expenses, and other payables	\$ 43,074	\$ 86,064	\$ 28,059	\$ 117,492	\$ 17,051	\$ 14,731
Deferred revenue and rent	17,474	44,776	18,850	7,814	3,937	16,687
Grants payable, net	383,383	37,500	-	-	-	12,500
Intercompany payable, net	28,007	138,964	114,863	457,238	24,234	63,055
Total liabilities	<u>471,938</u>	<u>307,304</u>	<u>161,772</u>	<u>582,544</u>	<u>45,222</u>	<u>106,973</u>
Total net assets	1,199,378	2,088,120	1,309,325	765,004	281,832	519,696
Total liabilities and net assets	<u>\$ 1,671,316</u>	<u>\$ 2,395,424</u>	<u>\$ 1,471,097</u>	<u>\$ 1,347,548</u>	<u>\$ 327,054</u>	<u>\$ 626,669</u>

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Statement of Financial Position by Affiliate (continued)

	San Diego	San Francisco Bay Area	South Florida	St. Louis	Tarrant County	Tulsa
Assets						
Cash, cash equivalents, and restricted cash	\$ 927,416	\$ 645,894	\$ 1,368,810	\$ 660,836	\$ 838,268	\$ 718,163
Investments	-	-	-	-	716,266	-
Receivables, net	198,232	5,857	94,238	110,173	160,668	28,169
Prepaid expenses and other assets	21,487	6,500	-	2,500	10,238	59,856
Property, equipment, and intangible assets, net	15,858	-	-	-	-	-
Total assets	<u>\$ 1,162,993</u>	<u>\$ 658,251</u>	<u>\$ 1,463,048</u>	<u>\$ 773,509</u>	<u>\$ 1,725,440</u>	<u>\$ 806,188</u>
Liabilities						
Accounts payable, accrued expenses, and other payables	\$ 62,420	\$ 24,806	\$ 19,545	\$ 11,194	\$ 11,573	\$ 32,550
Deferred revenue and rent	9,094	-	-	18,066	17,177	-
Grants payable, net	229,000	-	10,035	-	388,592	274,577
Intercompany payable, net	54,585	26,223	224,280	88,565	158,344	114,296
Total liabilities	<u>355,099</u>	<u>51,029</u>	<u>253,860</u>	<u>117,825</u>	<u>575,686</u>	<u>421,423</u>
Total net assets	807,894	607,222	1,209,188	655,684	1,149,754	384,765
Total liabilities and net assets	<u>\$ 1,162,993</u>	<u>\$ 658,251</u>	<u>\$ 1,463,048</u>	<u>\$ 773,509</u>	<u>\$ 1,725,440</u>	<u>\$ 806,188</u>

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Statement of Financial Position by Affiliate (continued)

	Western New York	Total Affiliates	Headquarters	Eliminations	Consolidated Total
Assets					
Cash, cash equivalents, and restricted cash	\$ 823,179	\$ 45,879,779	\$ 16,576,575	\$ –	\$ 62,456,354
Investments	–	9,331,292	106,530,043	–	115,861,335
Receivables, net	20,164	7,467,094	25,407,636	(7,249,167)	25,625,563
Prepaid expenses and other assets	658	889,958	1,742,896	–	2,632,854
Property, equipment, and intangible assets, net	–	188,673	804,736	–	993,409
Total assets	<u>\$ 844,001</u>	<u>\$ 63,756,796</u>	<u>\$ 151,061,886</u>	<u>\$ (7,249,167)</u>	<u>\$ 207,569,515</u>
Liabilities					
Accounts payable, accrued expenses, and other payables	\$ 25,835	\$ 2,598,168	\$ 5,438,864	\$ –	\$ 8,037,032
Deferred revenue and rent	22,345	750,237	187,031	–	937,268
Grants payable, net	215,411	5,586,882	40,205,042	–	45,791,924
Intercompany payable, net	71,663	5,409,474	1,839,693	(7,249,167)	–
Total liabilities	<u>335,254</u>	<u>14,344,761</u>	<u>47,670,630</u>	<u>(7,249,167)</u>	<u>54,766,224</u>
Total net assets	508,747	49,412,035	103,391,256	–	152,803,291
Total liabilities and net assets	<u>\$ 844,001</u>	<u>\$ 63,756,796</u>	<u>\$ 151,061,886</u>	<u>\$ (7,249,167)</u>	<u>\$ 207,569,515</u>

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Schedule of Revenue and Functional Expenses by Affiliate

Year Ended March 31, 2020

	Arkansas	Austin	Baton Rouge	Boise	Central & South Jersey	Charlotte
Public support and revenue:						
Contributions	\$ 294,133	\$ 696,737	\$ 427,687	\$ 113,700	\$ 832,113	\$ 778,910
Races, walks, and 3-day series	1,877,523	1,495,233	744,247	441,040	827,047	1,398,597
Other fundraising	33,030	5,776	400	1,249	1,334	74,061
Direct benefits	(220,222)	(221,577)	(143,294)	(78,816)	(131,529)	(287,304)
Interest, dividends, gains (losses)	2,880	10,479	108	647	-	15,094
Other	150	68,089	67,790	-	-	100,050
Total net public support and revenue	1,987,494	2,054,737	1,096,938	477,820	1,528,965	2,079,408
Expenses:						
Program services:						
Education and patient services	484,232	700,377	488,329	267,476	315,491	480,001
Research	222,074	243,524	109,955	63,055	286,156	334,463
Treatment services	-	-	700	18,333	23,500	159,259
Health screening services	-	55,782	-	38,577	-	94,962
Total program services	706,306	999,683	598,984	387,441	625,147	1,068,685
Supporting services:						
Fundraising costs	799,868	778,917	291,552	173,387	116,532	232,122
General and administrative	68,238	129,292	158,528	37,022	206,034	371,858
Total supporting services	868,106	908,209	450,080	210,409	322,566	603,980
Total expenses	1,574,412	1,907,892	1,049,064	597,850	947,713	1,672,665
Change in net assets	413,082	146,845	47,874	(120,030)	581,252	406,743
Net assets at beginning of year	512,839	843,245	309,551	362,492	354,985	653,772
Net assets at end of year	\$ 925,921	\$ 990,090	\$ 357,425	\$ 242,462	\$ 936,237	\$ 1,060,515

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Schedule of Revenue and Functional Expenses by Affiliate (continued)

	Chicagoland Area	Coastal Georgia	Columbus	Connecticut	Dallas County	Denver Metropolitan
Public support and revenue:						
Contributions	\$ 1,316,137	\$ 427,860	\$ 408,649	\$ 673,300	\$ 475,380	\$ 458,860
Races, walks, and 3-day series	633,323	428,721	2,082,710	937,104	2,085,886	1,311,550
Other fundraising	1,191	4,428	-	12,163	235	-
Direct benefits	(107,004)	(45,345)	(161,659)	(111,723)	(148,120)	(73,310)
Interest, dividends, gains (losses)	1,515	(634)	14,363	8,063	20,256	32,890
Other	-	-	16,250	-	50	50
Total net public support and revenue	1,845,162	815,030	2,360,313	1,518,907	2,433,687	1,730,040
Expenses:						
Program services:						
Education and patient services	674,959	146,795	1,732,814	637,790	473,946	727,383
Research	321,950	144,881	386,156	147,403	297,910	218,212
Treatment services	-	48,104	-	-	544,472	-
Health screening services	-	68,297	-	45,000	252,464	-
Total program services	996,909	408,077	2,118,970	830,193	1,568,792	945,595
Supporting services:						
Fundraising costs	364,064	111,746	491,429	516,824	962,262	547,692
General and administrative	136,812	92,064	85,502	130,849	41,167	149,982
Total supporting services	500,876	203,810	576,931	647,673	1,003,429	697,674
Total expenses	1,497,785	611,887	2,695,901	1,477,866	2,572,221	1,643,269
Change in net assets	347,377	203,143	(335,588)	41,041	(138,534)	86,771
Net assets at beginning of year	1,384,166	329,825	2,505,207	657,623	1,030,630	1,601,943
Net assets at end of year	\$ 1,731,543	\$ 532,968	\$ 2,169,619	\$ 698,664	\$ 892,096	\$ 1,688,714

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Schedule of Revenue and Functional Expenses by Affiliate (continued)

	Des Moines	Grand Rapids	Greater Atlanta	Greater Cincinnati	Greater Detroit	Greater Evansville
Public support and revenue:						
Contributions	\$ 199,430	\$ 577,543	\$ 1,921,184	\$ 210,443	\$ 202,734	\$ 230,268
Races, walks, and 3-day series	863,895	177,488	974,486	278,372	784,489	436,489
Other fundraising	7,088	-	40	-	639	2,628
Direct benefits	(166,910)	(63,468)	(136,849)	(3,678)	(95,285)	(97,463)
Interest, dividends, gains (losses)	(6,892)	988	(135)	2,375	-	630
Other	-	-	-	-	-	-
Total net public support and revenue	896,611	692,551	2,758,726	487,512	892,577	572,552
Expenses:						
Program services:						
Education and patient services	313,955	310,194	730,676	145,027	230,105	212,233
Research	115,948	108,030	467,843	129,187	71,291	54,425
Treatment services	2,700	40,815	86,500	-	124,659	-
Health screening services	-	244	24,349	25,463	48,483	-
Total program services	432,603	459,283	1,309,368	299,677	474,538	266,658
Supporting services:						
Fundraising costs	323,650	80,194	277,504	61,782	300,865	216,743
General and administrative	64,140	125,568	262,662	74,574	146,258	80,807
Total supporting services	387,790	205,762	540,166	136,356	447,123	297,550
Total expenses	820,393	665,045	1,849,534	436,033	921,661	564,208
Change in net assets	76,218	27,506	909,192	51,479	(29,084)	8,344
Net assets at beginning of year	721,206	392,144	1,161,839	147,517	703,258	148,087
Net assets at end of year	\$ 797,424	\$ 419,650	\$ 2,071,031	\$ 198,996	\$ 674,174	\$ 156,431

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Schedule of Revenue and Functional Expenses by Affiliate (continued)

	Greater Kansas City	Greater Nashville	Greater New York City	Greater Richmond	Greater Roanoke	Hawaii
Public support and revenue:						
Contributions	\$ 267,715	\$ 449,725	\$ 1,120,447	\$ 398,192	\$ 592,267	\$ 400,109
Races, walks, and 3-day series	619,510	886,532	3,607,734	751,648	412,972	775,477
Other fundraising	700	3,487	-	434	50	11,078
Direct benefits	(61,417)	(99,623)	(285,930)	(54,000)	(60,799)	(239,167)
Interest, dividends, gains (losses)	(15,833)	5,350	7,455	2,675	303	244
Other	-	-	293,932	-	-	-
Total net public support and revenue	810,675	1,245,471	4,743,638	1,098,949	944,793	947,741
Expenses:						
Program services:						
Education and patient services	307,243	342,165	1,870,514	360,214	242,053	294,187
Research	101,075	158,438	393,035	129,616	133,952	116,332
Treatment services	-	-	15,000	40,000	8,261	-
Health screening services	27,760	-	-	-	-	-
Total program services	436,078	500,603	2,278,549	529,830	384,266	410,519
Supporting services:						
Fundraising costs	237,503	386,550	2,015,267	345,580	203,859	328,021
General and administrative	74,769	87,178	393,825	126,394	92,795	30,206
Total supporting services	312,272	473,728	2,409,092	471,974	296,654	358,227
Total expenses	748,350	974,331	4,687,641	1,001,804	680,920	768,746
Change in net assets	62,325	271,140	55,997	97,145	263,873	178,995
Net assets at beginning of year	467,923	398,824	1,916,845	441,534	464,805	186,760
Net assets at end of year	\$ 530,248	\$ 669,964	\$ 1,972,842	\$ 538,679	\$ 728,678	\$ 365,755

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Schedule of Revenue and Functional Expenses by Affiliate (continued)

	Houston	Indianapolis	Inland Empire	Knoxville	Las Vegas	Los Angeles County
Public support and revenue:						
Contributions	\$ 628,951	\$ 484,611	\$ 380,389	\$ 285,238	\$ 231,612	\$ 345,235
Races, walks, and 3-day series	1,912,475	1,077,798	469,322	645,425	269,735	1,117,438
Other fundraising	-	-	-	-	1,595	2,432
Direct benefits	(199,415)	(247,122)	(60,515)	(87,672)	(14,650)	(72,913)
Interest, dividends, gains (losses)	1,189	(50,744)	292	262	1,183	627
Other	5,894	-	-	-	-	81,698
Total net public support and revenue	2,349,094	1,264,543	789,488	843,253	489,475	1,474,517
Expenses:						
Program services:						
Education and patient services	878,978	426,197	278,008	250,709	133,865	544,546
Research	256,118	189,971	113,638	115,183	70,690	162,195
Treatment services	25,000	-	20,000	-	71,674	25,000
Health screening services	88,274	-	-	-	23,139	134,540
Total program services	1,248,370	616,168	411,646	365,892	299,368	866,281
Supporting services:						
Fundraising costs	794,151	441,720	198,301	302,656	72,708	524,300
General and administrative	209,701	70,088	36,031	44,634	69,557	123,788
Total supporting services	1,003,852	511,808	234,332	347,290	142,265	648,088
Total expenses	2,252,222	1,127,976	645,978	713,182	441,633	1,514,369
Change in net assets	96,872	136,567	143,510	130,071	47,842	(39,852)
Net assets at beginning of year	552,955	965,849	454,893	219,006	226,934	656,127
Net assets at end of year	\$ 649,827	\$ 1,102,416	\$ 598,403	\$ 349,077	\$ 274,776	\$ 616,275

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Schedule of Revenue and Functional Expenses by Affiliate (continued)

	Louisville	Lowcountry (Charleston)	Maryland	Memphis Mid-South	Miami – Ft. Lauderdale	Milwaukee
Public support and revenue:						
Contributions	\$ 167,997	\$ 344,834	\$ 564,580	\$ 349,029	\$ 333,323	\$ 535,706
Races, walks, and 3-day series	281,172	537,453	945,748	1,007,088	987,958	1,294,627
Other fundraising	3,615	–	911	375	–	–
Direct benefits	(98,786)	(92,656)	(70,688)	(133,340)	(180,642)	(98,179)
Interest, dividends, gains (losses)	872	4,981	6,087	–	1,445	5,863
Other	–	–	–	50	–	–
Total net public support and revenue	354,870	794,612	1,446,638	1,223,202	1,142,084	1,738,017
Expenses:						
Program services:						
Education and patient services	210,132	355,134	843,737	333,295	369,368	734,843
Research	16,688	100,701	99,515	198,515	184,735	217,120
Treatment services	–	–	–	154,455	138,727	229,974
Health screening services	–	–	–	226,359	81,071	344,127
Total program services	226,820	455,835	943,252	912,624	773,901	1,526,064
Supporting services:						
Fundraising costs	192,980	284,311	513,495	315,285	217,642	425,727
General and administrative	38,068	57,486	320,623	96,441	57,438	141,769
Total supporting services	231,048	341,797	834,118	411,726	275,080	567,496
Total expenses	457,868	797,632	1,777,370	1,324,350	1,048,981	2,093,560
Change in net assets	(102,998)	(3,020)	(330,732)	(101,148)	93,103	(355,543)
Net assets at beginning of year	555,817	344,439	718,319	468,604	561,428	1,679,294
Net assets at end of year	\$ 452,819	\$ 341,419	\$ 387,587	\$ 367,456	\$ 654,531	\$ 1,323,751

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Schedule of Revenue and Functional Expenses by Affiliate (continued)

	Minnesota	NC Triangle	Nebraska	New Orleans	North Central Alabama	North Jersey
Public support and revenue:						
Contributions	\$ 382,993	\$ 631,317	\$ 683,370	\$ 244,386	\$ 94,971	\$ 794,364
Races, walks, and 3-day series	1,469,724	886,072	847,214	446,443	626,194	374,692
Other fundraising	9,156	2,825	-	4,344	-	-
Direct benefits	(229,799)	(107,834)	(94,837)	(91,551)	(47,994)	(76,522)
Interest, dividends, gains (losses)	2,345	5,880	6,905	43	271	9,193
Other	1,000	217,000	-	-	4,830	-
Total net public support and revenue	1,635,419	1,635,260	1,442,652	603,665	678,272	1,101,727
Expenses:						
Program services:						
Education and patient services	359,553	425,103	309,664	218,693	298,732	428,621
Research	180,531	150,655	207,170	100,167	75,071	148,413
Treatment services	256,856	120,126	-	-	-	-
Health screening services	60,348	-	48,825	10	10,000	-
Total program services	857,288	695,884	565,659	318,870	383,803	577,034
Supporting services:						
Fundraising costs	862,564	361,623	308,946	98,707	271,396	395,418
General and administrative	75,698	90,018	178,931	37,683	29,683	166,967
Total supporting services	938,262	451,641	487,877	136,390	301,079	562,385
Total expenses	1,795,550	1,147,525	1,053,536	455,260	684,882	1,139,419
Change in net assets	(160,131)	487,735	389,116	148,405	(6,610)	(37,692)
Net assets at beginning of year	867,935	397,303	935,577	165,906	352,121	1,049,477
Net assets at end of year	\$ 707,804	\$ 885,038	\$ 1,324,693	\$ 314,311	\$ 345,511	\$ 1,011,785

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Schedule of Revenue and Functional Expenses by Affiliate (continued)

	North Texas	Northeast Ohio	Northwest Ohio	Orange County	Oregon & SW Washington	Ozark
Public support and revenue:						
Contributions	\$ 279,306	\$ 377,843	\$ 218,756	\$ 1,777,561	\$ 661,100	\$ 562,515
Races, walks, and 3-day series	874,306	466,649	952,792	1,099,680	723,845	1,046,784
Other fundraising	3,882	115	1,045	1,773	13,356	-
Direct benefits	(152,990)	(39,325)	(161,469)	(272,183)	(108,758)	(226,404)
Interest, dividends, gains (losses)	7,081	5,314	9,254	43,725	476	6,718
Other	1,684	-	23,676	189,056	-	-
Total net public support and revenue	1,013,269	810,596	1,044,054	2,839,612	1,290,019	1,389,613
Expenses:						
Program services:						
Education and patient services	316,088	515,062	592,791	1,283,423	1,091,317	404,649
Research	108,562	103,095	151,866	220,909	157,568	238,890
Treatment services	200,221	41,634	-	237,588	2,000	347,267
Health screening services	100,539	47,157	-	397,202	5,998	37,457
Total program services	725,410	706,948	744,657	2,139,122	1,256,883	1,028,263
Supporting services:						
Fundraising costs	509,675	218,411	324,110	427,070	958,492	388,941
General and administrative	64,585	129,234	48,329	265,846	61,177	78,750
Total supporting services	574,260	347,645	372,439	692,916	1,019,669	467,691
Total expenses	1,299,670	1,054,593	1,117,096	2,832,038	2,276,552	1,495,954
Change in net assets	(286,401)	(243,997)	(73,042)	7,574	(986,533)	(106,341)
Net assets at beginning of year	949,960	564,202	839,374	2,197,461	1,355,719	649,845
Net assets at end of year	\$ 663,559	\$ 320,205	\$ 766,332	\$ 2,205,035	\$ 369,186	\$ 543,504

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Schedule of Revenue and Functional Expenses by Affiliate (continued)

	Peoria Memorial	Philadelphia	Pittsburgh	Puget Sound	Sacramento Valley	San Antonio
Public support and revenue:						
Contributions	\$ 1,458,417	\$ 1,114,332	\$ 514,992	\$ 1,606,185	\$ 232,645	\$ 273,615
Races, walks, and 3-day series	872,548	1,253,586	1,193,126	344,181	466,570	533,834
Other fundraising	17,038	2,088	–	12,800	2,206	6,499
Direct benefits	(114,995)	(497,879)	(207,774)	(236,935)	(66,256)	(207,194)
Interest, dividends, gains (losses)	2,375	20,231	49,804	12,886	–	1,004
Other	15,374	1,000	–	1,000	77,338	–
Total net public support and revenue	2,250,757	1,893,358	1,550,148	1,740,117	712,503	607,758
Expenses:						
Program services:						
Education and patient services	581,794	1,237,749	634,026	1,019,439	195,141	232,447
Research	411,852	240,040	216,667	216,387	76,544	131,798
Treatment services	74,209	814	40,000	125,000	–	–
Health screening services	146,583	–	280,000	–	131,531	–
Total program services	1,214,438	1,478,603	1,170,693	1,360,826	403,216	364,245
Supporting services:						
Fundraising costs	408,262	1,393,611	653,419	564,004	277,040	298,618
General and administrative	33,034	115,110	91,939	186,867	109,729	18,974
Total supporting services	441,296	1,508,721	745,358	750,871	386,769	317,592
Total expenses	1,655,734	2,987,324	1,916,051	2,111,697	789,985	681,837
Change in net assets	595,023	(1,093,966)	(365,903)	(371,580)	(77,482)	(74,079)
Net assets at beginning of year	604,355	3,182,086	1,675,228	1,136,584	359,314	593,775
Net assets at end of year	\$ 1,199,378	\$ 2,088,120	\$ 1,309,325	\$ 765,004	\$ 281,832	\$ 519,696

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Schedule of Revenue and Functional Expenses by Affiliate (continued)

	San Diego	San Francisco Bay Area	South Florida	St. Louis	Tarrant County	Tulsa
Public support and revenue:						
Contributions	\$ 1,057,730	\$ 363,150	\$ 1,086,282	\$ 322,316	\$ 604,915	\$ 420,006
Races, walks, and 3-day series	1,185,620	194,613	1,364,825	801,967	581,535	800,235
Other fundraising	8,024	297	-	-	3,000	4,984
Direct benefits	(136,305)	(96,960)	(162,867)	(83,108)	(104,009)	(132,000)
Interest, dividends, gains (losses)	3,770	61	2,485	353	(14,291)	584
Other	1,000	-	129,311	-	-	-
Total net public support and revenue	2,119,839	461,161	2,420,036	1,041,528	1,071,150	1,093,809
Expenses:						
Program services:						
Education and patient services	793,547	156,439	627,694	149,087	267,706	303,708
Research	218,048	50,229	161,097	170,465	192,929	134,311
Treatment services	316,590	15,000	50,000	-	353,426	87,857
Health screening services	75,482	-	-	-	115,689	71,871
Total program services	1,403,667	221,668	838,791	319,552	929,750	597,747
Supporting services:						
Fundraising costs	643,098	165,465	818,632	291,676	160,013	398,374
General and administrative	84,847	35,129	280,844	61,919	39,225	119,143
Total supporting services	727,945	200,594	1,099,476	353,595	199,238	517,517
Total expenses	2,131,612	422,262	1,938,267	673,147	1,128,988	1,115,264
Change in net assets	(11,773)	38,899	481,769	368,381	(57,838)	(21,455)
Net assets at beginning of year	819,667	568,323	727,419	287,303	1,207,592	406,220
Net assets at end of year	\$ 807,894	\$ 607,222	\$ 1,209,188	\$ 655,684	\$ 1,149,754	\$ 384,765

The Susan G. Komen Breast Cancer Foundation, Inc.
dba Susan G. Komen and Affiliates

Consolidating Schedule of Revenue and Functional Expenses by Affiliate (continued)

	Western New York	Total Affiliates	Headquarters	Eliminations	Consolidated Total
Public support and revenue:					
Contributions	\$ 415,763	\$ 34,303,858	\$ 114,014,331	\$ (11,229,901)	\$ 137,088,288
Races, walks, and 3-day series	796,285	55,581,632	17,065,218	-	72,646,850
Other fundraising	8,193	270,564	183,725	-	454,289
Direct benefits	(317,479)	(8,424,497)	(5,871,218)	-	(14,295,715)
Interest, dividends, gains (losses)	2,083	253,428	(13,736,680)	-	(13,483,252)
Other	-	1,296,272	685,424	(1,333,505)	648,191
Total net public support and revenue	904,845	83,281,257	112,340,800	(12,563,406)	183,058,651
Expenses:					
Program services:					
Education and patient services	452,893	30,742,337	76,043,254	(239,366)	106,546,225
Research	148,022	10,691,266	5,473,057	(10,691,266)	5,473,057
Treatment services	70,544	4,116,265	1,709,831	(538,646)	5,287,450
Health screening services	141,342	3,248,925	687,693	(159,046)	3,777,572
Total program services	812,801	48,798,793	83,913,835	(11,628,324)	121,084,304
Supporting services:					
Fundraising costs	304,417	25,949,171	16,961,768	(312,539)	42,598,400
General and administrative	70,729	6,906,538	24,694,826	(622,543)	30,978,821
Total supporting services	375,146	32,855,709	41,656,594	(935,082)	73,577,221
Total expenses	1,187,947	81,654,502	125,570,429	(12,563,406)	194,661,525
Change in net assets	(283,102)	1,626,755	(13,229,629)	-	(11,602,874)
Net assets at beginning of year	791,849	47,785,280	116,620,885	-	164,406,165
Net assets at end of year	\$ 508,747	\$ 49,412,035	\$ 103,391,256	\$ -	\$ 152,803,291

About EY

EY is a global leader in assurance, tax, strategy, transaction and consulting services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. For more information about our organization, please visit ey.com.

© 2020 Ernst & Young LLP.
All Rights Reserved.

ey.com